Viridian Therapeutics, Inc.\DE (VRDN) Non Operating Income (2016 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Non Operating Income of $11.3 million for Q1 2026, up 62.04% year-over-year from $7.0 million in Q1 2025, and up 370.68% quarter-over-quarter from $2.4 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Non Operating Income (2016 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Non Operating Income history runs 11 years deep, the most recent figure standing at $11.3 million for Q1 2026.
- In Q1 2026, Non Operating Income rose 62.04% year-over-year to $11.3 million; the TTM figure through Mar 2026 stood at $25.1 million (down 12.47% YoY), while the FY2025 annual figure was $20.8 million, down 28.51% from the prior year.
- Non Operating Income for Q1 2026 stood at $11.3 million, up from $2.4 million in the prior quarter.
- The five-year high for Non Operating Income was $11.3 million in Q1 2026, with the low at $73000.0 in Q2 2022.
- The 5-year median for Non Operating Income is $4.6 million (2023), against an average of $4.8 million.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income soared 5669.86% in 2023, then plunged 69.1% in 2025.
- Viridian Therapeutics, Inc.\DE's Non Operating Income stood at $3.3 million in 2022, then surged by 40.75% to $4.6 million in 2023, then soared by 67.76% to $7.7 million in 2024, then slumped by 69.1% to $2.4 million in 2025, then jumped by 370.68% to $11.3 million in 2026.
- Business Quant data shows VRDN's Non Operating Income at $11.3 million in Q1 2026, $2.4 million in Q4 2025, and $5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | -851,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -851,000.00 |
| Mar 31, 2026 | 11.27 Mn |
| Dec 31, 2025 | 2.39 Mn |
| Sep 30, 2025 | 5.41 Mn |
| Jun 30, 2025 | 6.03 Mn |
| Mar 31, 2025 | 6.95 Mn |
| Dec 31, 2024 | 7.75 Mn |
| Sep 30, 2024 | 6.79 Mn |
| Jun 30, 2024 | 7.19 Mn |
| Mar 31, 2024 | 7.36 Mn |
| Dec 31, 2023 | 4.62 Mn |
| Sep 30, 2023 | 3.56 Mn |
| Jun 30, 2023 | 4.21 Mn |
| Mar 31, 2023 | 4.32 Mn |
| Dec 31, 2022 | 3.28 Mn |
| Sep 30, 2022 | 880,000.00 |
| Jun 30, 2022 | 73,000.00 |
| Mar 31, 2022 | 196,000.00 |
| Dec 31, 2021 | 135,000.00 |
| Sep 30, 2021 | 91,000.00 |